Efficacy of tailored Helicobacter pylori eradication therapy based on susceptibility to antimicrobial agents

Efficacy of tailored Helicobacter pylori eradication therapy based on susceptibility to antimicrobial agents - Efficacy of tailored HP eradication based on susceptibility to antimicrobial agents

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030270

Enrollment

310

Registered

2017-12-05

Start date

2016-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori-associated gastritis

Interventions

Conventional:7 days VPZ20mg/AMPC750mg/CAM200mg bid Tailored: 7 days 1. CAM-S: VPZ20mg/AMPC750mg/CAM200mg bid 2. CAM-R: VPZ20mg/AMPC750mg/MNZ250mg bid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age; mere than 20 years 2. With informed consent 3. Positive for culture test of H. pylori

Exclusion criteria

Exclusion criteria: 1. With malignant diseases 2. Negative for culture test 3. With severe liver disease 4. No informed consent 5. Not suitable by judgement of Medical Doctor

Design outcomes

Primary

Measure	Time frame
Eradication rate of tailored eradication therapy based on susceptibility to antimicrobial agents.	—

Secondary

Measure	Time frame
1. Eradication rate of tailored tailored H. pylori eradication therapy based on susceptibility to antimicrobial agents among different CYP2C19, CYP3A4, CYP3A5 genotypes. 2.Change of abdominal symptoms between before and after eradication therapy	—

Countries

Japan

Contacts

Public ContactMitsushige Sugimoto

Shiga University of Medical Science Hospital Division of Digestive Endoscopy

sugimo@belle.shiga-med.ac.jp077-548-2618

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026